CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Lifestyle Modifications for Preventing and Treating Heart Failure Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Dapagliflozin for treating chronic heart failure with reduced ejection fraction The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure

JOURNAL: Article Link

经皮冠状动脉介入治疗后的积极降脂治疗--目标人群以及如何开展?

作者:Zhen-Vin Lee等 译者:左广峰 审校:姜潇

摘要

尽管经皮冠状动脉介入治疗 (PCI) 对阻塞性冠状动脉疾病的疗效是确切的,但考虑到非手术相关的其他重要危险因素的控制程度,尚不能确保长期预后。动脉粥样硬化作为血脂异常的结果,其发展导致的风险具有连续性,因此对接受PCI的患者采取二级预防措施,对于降低手术失败以及心血管事件的风险尤为重要。本综述通过总结最新临床指南推荐,强调三种主流降脂疗法相关理论和证据(即他汀类药物、依折麦布和前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型(PCSK9)抑制剂),概述以二级预防为目的降脂治疗现状。同时,揭示了血脂异常二级预防在实践过程中的挑战和问题,如对未达最佳血脂标准及依从性差等问题提出了可行性方案。